


DFW



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
3829.03-1

In Re Application Of: **WECHTER, ET AL.**

Serial No.
10/763,111

Filing Date
JANUARY 21, 2004

Examiner
N/A

Group Art Unit
N/A

Title: **FAT SUBSTITUTES**

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

1. TRANSMITTAL LETTER;
2. TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT;
3. PTO FORM 1449;
4. COPIES OF REFERENCES CITED; AND
5. POSTCARD.

in the above identified application.

- ☐ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **16-1331** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.


Signature

Dated: **MAY 10, 2004**

HANA VERNY (REG. NO. 30,518)
PETERS, VERNY, JONES & SCHMITT, L.L.P.
425 SHERMAN AVENUE, SUITE 230
PALO ALTO, CA 94306
TEL: (650)324-1677
FAX: (650)324-1678

I certify that this document and fee is being deposited on **MAY 10, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

MELINDA A. TOMPKINS

Typed or Printed Name of Person Mailing Correspondence

cc:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

MAY 14 2004

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

3829.03-1

In Re Application Of: **WECHTER, ET AL.**

Serial No.

10/763,111

Filing Date

JANUARY 21, 2004

Examiner

N/A

Group Art Unit

N/A

Title: **FAT SUBSTITUTES**

Address to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450****37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

MAY 14 2004

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

3829.03-1

Re Application: WECHTER, ET AL.

Serial No.

10/763,111

Filing Date

JANUARY 21, 2004

Examiner

N/A

Group Art Unit

N/A

FAT SUBSTITUTES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 16-1331 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on MAY 10, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

MELINDA A. TOMPKINS

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: MAY 10, 2004

HANA VERNY (REG. NO. 30,518)

PETERS, VERNY, JONES & SCHMITT, L.L.P.

425 SHERMAN AVENUE, SUITE 230

PALO ALTO, CA 94306

TELEPHONE: (650)324-1677

FACSIMILE: (650)324-1678

CC:

FOR PTO-1449 (Modified)

ATTY. DOCKET NO.
3829.03-1SERIAL NO.
10/763,111

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANTS INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)

APPLICANT : WECHTER, ET AL.

FILING DATE : JANUARY 21, 2004

GROUP N/A

REFERENCE DESIGNATION


U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
			US			

OTHER

ART (Including Author, Title, Date, Pertinent Pages, Etc.)

A	Stokke, O., et al. Biochim. Biophys. Acta 144, 271-84 (1967) α -Oxidation as an alternative pathway for the degradation of Branched-Chain Fatty acids in man and its failure in Patients with Refsum's disease
B	Steinberg, D., et al. J. Lipid Res. 7, 684-91 (1966) Effects of dietary phytol and phytanic acid in animals
C	McCarty, M.F. Med. Hypothesis 56, 217-19 (2001) The chlorophyll metabolite phytanic acid is a natural rexinoid - potential for treatment and prevention of diabetes
D	Verhoeven, N.M., et al. Eur. J. Pediatr. 156, S83-87 (1997) Stable isotope studies of phytanic acid α -Oxidation: in vivo production of formic acid
E	Mize, C.E., et al. Biochim. Biophys. Acta 176, 720-39 (1969) A major pathway for the mammalian oxidative degradation of phytanic acid
F	Baxter, J.H. J. Lipid Res. 9, 636-641 (1968) Absorption of chlorophyll phytol in normal man and in patients with Refsum's disease
G	Wierzbicki, A.S., et al. J. Lipid Res. 44, 148-188 (2003) Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease
H	Wanders, R.J.A., et al. Biochim. Biophys. Acta 1631, 119-135 (2003) Phytanic acid α -Oxidation, new insights into an old problem: a review
I	Ferdinandusse, S., et al. J. Lipid Res. 43, 438-444 (2002) Stereochemistry of the peroxisomal branched-chain fatty acid α - and β -oxidation systems in patients suffering from different peroxisomal disorders
J	Verhoeven, N.M. et al. J. Lipid Res. 39, 66-74 (1998) Phytanic acid and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts
K	Van Veldhoven P.P., et al. Biochem. Soc. Transac. 29, 292-98 (2001) Further insights into peroxisomal lipid breakdown via α - and β -oxidation
L	Verhoeven, N.M. and Jakobs, C. Prog. Lipid Res. 40, 453-466 (2001) Human Metabolism of phytanic acid and pristanic acid
M	Schluter, A., et al. FEBS Lett. 517, 83-6 (2002) Phytanic acid, but not pristanic acid mediates the positive effects of phytol derivatives on brown adipocyte differentiation
N	Schluter, A., et al. Biochem. J. 362, 61-69 (2002) Phytanic acid, a novel activator of uncoupling protein-1 gene transcription and brown adipocyte differentiation
O	Verhoeven, N.M. et al. J. Lipid Res. 40, 260-6 (1999) Analysis of pristanic acid β -oxidation intermediates in plasma from healthy controls and patients affected with peroxisomal disorders by stable isotope dilution gas chromatography mass spectrometry
P	Tserng, K.-Y., et al. J. Lipid Res. 31, 763-771 (1990) Abnormal urinary excretion of unsaturated dicarboxylic acids in patients with medium-chain acyl-CoA dehydrogenase deficiency
Q	Jin, S.-J. and Tserng, K.-Y. J. Lipid Res. 30, 1611-1619 (1989) Identification of isomeric unsaturated medium-chain dicarboxylic acids in human urine
R	Stellaard, F., et al. Clinica Chimica Acta 192, 133-144 (1990) Stable isotope dilution analysis of very long chain fatty acids in plasma, urine and amniotic fluid by electron capture negative ion mass fragmentography
S	ten Brink, H.J., et al. J. Lipid Res. 33, 41-7 (1992) Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography
T	Zhou, Y.-T., et al. Proc. Natl. Acad. Sci. USA 96, 23941-2395 (1999) Reversing adipocyte differentiation: Implications for treatment of obesity

	U	Young, S.P., et al. Clinical Science 101, 697-705 (2001) Effects of phytanic acid on the vitamin E status, lipid composition, and physical properties of retinal cell membranes: implications for adult Refsum disease	✓
		Zomer, A.W.M., et al., J. Lipid Res. 41, 1801-7 (2000) Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor α	✓
		Kase, B.F., et al. Anal. Biochem. 196, 95-8 (1991) Separation of phytanic and pristanic acid by high-pressure liquid chromatography: application of the method	✓
	X	Schluter, A., et al., Internat. J. Obesity 26, 1277-1280 (2002) The chlorophyll-derived metabolite phytanic acid induces white adipocyte differentiation	✓
	Y	Gibbons, G.F. Prog. Lipid Res. 42, 479-497 (2003) Regulation of fatty acid and cholesterol synthesis: co-operation or competition?	✓
	Z	Rontani, J.-F., et al. Appl. Environ. Microb. 65, 5484-5492 (1999) Biodegradation of free phytol by bacterial communities isolated from marine sediments under aerobic and denitrifying conditions	✓
	AA	Paton, B.C., et al. J. Clin. Invest. 97, 681-688 (1996) Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal β -oxidation effects	✓
	BB	Jin, S.-J., et al. J. Biol. Chem 267, 119-125 (1992) Incomplete fatty acid oxidation, the production and epimerization of 3-hydroxy fatty acids	✓
	CC	Liebich, H.M., et al. J. Chromatog. 199, 181-189 (1980) Gas chromatography-mass spectrometry of saturated and unsaturated dicarboxylic acids in urine	✓
	DD	Vreken, P., et al. J. Chromatog. B 713, 281-7 (1998) Rapid stable isotope dilution analysis of very-long-chain fatty acids, pristanic acid and phytanic acid using gas chromatography-electron impact mass spectrometry	✓
	EE	Croes, K., et al. J. Lipid Res. 40, 601-6 (1999) Stereochemistry of the α -oxidation of 3-methyl-branched fatty acid in rat liver	✓
	FF	Croes, K., et al. Eur. J. Biochem. 240, 674-683 (1996) α -oxidation of 3-methyl-substituted fatty acid in rat liver, production of formic acid instead of CO_2 , cofactor requirements subcellular localization and formation of a 2-hydroxy-3-methylacyl-CoA intermediate	✓
	GG	Vanhove, G., et al. J. Biol. Chem. 266, 24670-5 (1991) Mitochondrial and peroxisomal β oxidation of the branched chain fatty acid 2-methylpalmitate in rat liver	✓
	HH	Foulon, V., et al. Proc. Natl. Acad. Sci. USA 96, 10039-10044 (1999) Purification, molecular cloning and expression of 2-hydroxyphytanoyl-CoA lyase, a peroxisomal thiamine pyrophosphate-dependent enzyme that catalyzes the carbon-carbon bond cleavage during α -oxidation of 3-methyl-branched fatty acids	✓
	II	Amery, L. et al. J. Lipid Res. 41, 1752-59 (2000) Mitochondrial and peroxisomal targeting of 2-methyl-CoA racemase in humans	✓
	JJ	Kotti, T.J., et al. J. Biol. Chem. 275, 20887-95 (2000) In mouse α -methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes	✓
	KK	Mukherji, M., et al. Prog. J. Lipid Res. 42, 359-76 (2003) The chemical biology of branched-chain lipid metabolism	✓
	LL	Shieh, W.-R. And Chen C.-S. J. Biol. Chem. 258, 3487-93 (1993) Purification and characterization of novel "2-arylpropionyl-CoA epimerases" from rat liver cytosol and mitochondria	✓
	MM	Reichel, C., et al. J. Pharmac. and Exptl. Therapeutics 51, 576-82 (1997) Molecular cloning and expression of a 2-arylpropionyl-Coenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen	✓
	NN	Reichel, C., et al. Biochem. Pharmacol. 50, 1803-6 (1995) 2-arylpropionyl-CoA epimerases: partial peptide sequence and tissue localization	✓
	OO	Ferdinandusse, S., et al. J. Lipid Res. 41, 1890-96 (2000) Subcellular localization and physiological role of α -methylacyl-CoA racemase	✓
	PP	Steinberg, D., et al. Biochem. Biophys. Res. Comm. 19, 783-789 (1965) Conversion of U- C^{14} -Phytol to phytanic acid and its oxidation in Hereditary atactica polyneuritisformis	✓
	QQ	Hansen, R.P., et al. Biochim. Biophys Acta 116, 178-80 (1966) The fate of phytanic acid when administered to rats	✓
	RR	Avigan, J. Biochim. Biophys Acta 116, 391-4 (1966) The presence of phytanic acid in normal human and animal plasma	✓
	SS	Mize, C.E., et al. J. Lipid Res. 7, 692-697 (1966) Metabolism of phytol U- C^{14} and phytanic acid-U- C^{14} in the rat	✓
	TT	Avigan, J., et al. Biochim. Biophys Res. Comm. 24, 838-844 (1966) Alpha -decarboxylation, an important pathway for degradation of phytanic acid in animals	✓
	UU	Avigan, J. Biochim. Biophys Acta 125, 607-10 (1966) Pristanic acid (2,6,10,14-tetramethylpentadecanoic acid) and phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) content of human and animal tissues	✓
	VV	Mize, C.E., et al. Biochem. Biophys. Res. Comm. 25, 359-365 (1966) A pathway for oxidative degradation of phytanic acid in mammals	✓
	WW	Baxter, J.H. and Steinberg, D. J. Lipid Res. 8, 615-20 (1967) Absorption of phytol from dietary chlorophyll in the rat	✓
	XX	Baxter, J.H. and Steinberg, D. J. Lipid Res. 9, 636-41 (1968) Absorption of chlorophyll phytol in normal man and in patients with Refsum's disease	✓



YY	Baxter, J.H. and Milne, G.W.A.-Biochim. Biophys. Acta. 176, 265-77 (1969) Phytanic acid: identification of five isomers in chemical and biological products of phytol
	Jansen, G.A. et al. Biochem. Biophys. Res. Comm. 283, 674-9 (2001) Identification of pristanal dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid α -oxidation pathway is localized in peroxisomes
	Ferdinanadusse, Ss., et al. 2-methyl branched-chain fatty acid β -oxidation in peroxisomes and mitochondria and the role of 2-methylacyl-CoA racemase therein. In New Avenues of Research in Fatty Acid Oxidation and Ketone Body Metabolism, Eaton and Quant Ed FAOKX Press, London 2001
BBB	Vanhooren, J.C.T., et al. Int. J. Biochem. 26, 1095-1101 (1994) Activation of 3-methyl-branched fatty acids in rat liver
CCC	Van Veldhoven, P.P. et al. FEBS Lett. 388, 80-84 (1996) Peroxisomal β -oxidation of 2-methyl-branched acyl-CoA esters: stereospecific recognition of the 2S-methyl compounds by trihydroxycoprostanoyl-CoA oxidase and pristanoyl-CoA oxidase
DDD	Dieuadie-Noubhani, M., et al. Biochem. J. 325, 367-73 (1997) Evidence that multifunctional protein 2, and not multifunctional protein 1, is involved in the peroxisomal β -oxidation of pristanic acid
EEE	Ackman, R.G., et al. Lipids 2, 357-362 (1967) The occurrence of diastereomers of phytanic and pristanic acids and their determination by gas-liquid chromatography
FFF	Dhopeswarkar, G.A. Prog. Lipid Res. 19, 107-118 (1981) Naturally occurring food toxicants: toxic lipids
GGG	Stokke O., et al. Scand. J. Clin. Lab. Invest. 46, 3-10 (1986) Disorders related to the metabolism of phytanic acid
HHH	van den Branden, C., et al. Pediat. Res. 20, 411-15 (1986) Phytol and peroxisome proliferation
III	Vallance, H. and Applegarth, D. Clin. Biochem. 27, 183-6 (1994) An improved method for quantification of very long chain fatty acids in plasma
JJJ	Schmitz, W., et al. Eur. J. Biochem. 222, 313-323 (1994) Purification and properties of an α -methylacyl-CoA racemase from rat liver
KKK	Pahan, K. and Singh, I. J. Lipid Res. 36, 986-997 (1995) Phytanic acid oxidation: topographical localization of phytanoyl-CoA ligase and transport of phytanic acid in human peroxisomes
LLL	Mihalik, S.J., et al. Eur. J. Biochem. 232, 545-551 (1995) Phytanic acid α -oxidation in rat liver peroxisomes
MMM	Watkins, P.A., et al. J. Lipid Res. 37, 2288-2295 (1996) Phytanic acid activation in rat liver peroxisomes is catalyzed by long-chain acyl-CoA synthetase
NNN	Schmitz, W. and Conzelmann, E. Eur. J. Biochem. 244, 434-440 (1997) Stereochemistry of peroxisomal and mitochondrial β -oxidation of α -methylacyl-CoAs
OOO	Clayton, P.T. Biochem. Soc. Trans. 29, 298-305 (2001) Clinical consequences of defects in peroxisomal β -oxidation
PPP	Little, J.M. et al. Drug Metab. Dispos. 30, 551-553 (2002) Glucuronidation of the dietary fatty acids, phytanic acid and docosahexaenoic acid, by human UDP-glucuronosyltransferases
QQQ	Heim, M. et al. FASEB J. 16, 718-720 (2002) Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes
RRR	Browne, G.S., et al. Biochem. Pharmacol. 57, 837-44 (1999) Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β -oxidation and oxidative phosphorylation by the non-steroidal inflammatory drugs ibuprofen, flurbiprofen and ketorolac
SSS	Dacremont, G., et al. J. Inher. Metab. Dis. 18, 76-83 (1995) Measurement of very long-chain fatty acids, phytanic and pristanic acid in plasma and cultured fibroblasts by gas chromatography
TTT	Rezanka, T. and Votruba, J. Anal. Chim. Acta 465, 273-297 (2002) Chromatography of very long-chain fatty acids from animal and plant kingdoms
UUU	Egge, H., et al. FEBS Lett. 2, 255-8 (1969) Minor constituents of human milk (I) identification of cyclohexaneundecanoic acid and phytanic acid in human milk fat by a combination gas chromatograph-mass spectrometer
VVV	Lough, A.K. Lipids 12, 115-9 (1976) The phytanic acid content of the lipids of bovine tissues and milk
WWW	Verhoeven, N.M., et al. Biochem. Biophys. Res. Comm. 237, 33-36 (1997) Resolution of the phytanic acid α -oxidation pathway: identification of pristanal as the product of the decarboxylation of 2-hydroxyphytanoyl-CoA
XXX	Brown, W.G. Org. React. 6, 469-509 (1951) Reductions by lithium aluminum hydride

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

